Understanding Antimicrobial Resistance and Its Economic Impact
Analysis of antimicrobial resistance and its economic impact, based on "The Broken Market": What is Antibiotic Resistance and How Does it Impact the Economy | Euronewsru.
OPEN SOURCEAntimicrobial resistance (AMR) poses a significant threat to public health and the economy, with projections indicating that by 2050, up to 40 million people could die annually from superbug infections. The economic impact of AMR in Europe is substantial, with costs estimated at around 12 billion euros each year due to longer hospital stays and increased healthcare services.
Shinogi Europe, a Japanese pharmaceutical company, has been focused on developing antimicrobials for nearly 150 years and stresses the urgent need for new antibiotics to address AMR. The emergence of superbugs is largely due to the overuse of antibiotics, which has enabled resistant bacteria to flourish, complicating the treatment of common infections.
Developing new antibiotics requires substantial investment, estimated at around 1 billion dollars, and typically takes 10 to 15 years, with a high failure rate of 95% for drug candidates. The current antibiotic market is unsustainable due to low pricing and limited usage aimed at preventing resistance, highlighting the need for new economic models and government incentives.
Investment incentives for antibiotic development include push incentives like grants and clinical trial support, as well as pull incentives such as subscription models that separate revenue from drug usage. The World Health Organization reports that there are approximately 15 drugs in development targeting superbugs, emphasizing the urgent need for improved conditions to attract pharmaceutical companies.
- Highlights the urgent need for new antibiotics to combat AMR
- Identifies significant economic costs associated with AMR in Europe
- Notes the unsustainable economic model for developing new antibiotics
- Points out the high failure rate and long development time for new drugs
- Acknowledges the role of over-prescription in the rise of superbugs
- Mentions the need for collaboration in addressing AMR
- Antimicrobial resistance (AMR) is a critical threat to public health and the economy, with projections indicating that by 2050, up to 40 million people could die annually from superbug infections
- Shinogi Europe, a Japanese pharmaceutical company, has been focused on developing antimicrobials for nearly 150 years and stresses the urgent need for new antibiotics to address AMR
- The emergence of superbugs is largely due to the overuse of antibiotics, which has enabled resistant bacteria to flourish, complicating the treatment of common infections
- In Europe, AMR incurs significant economic costs, estimated at around 12 billion euros annually, as patients require longer hospital stays and increased healthcare services due to resistant infections
- Without proactive measures and the introduction of new antibiotics, the mortality rate and economic burden associated with AMR are projected to escalate, underscoring the necessity for collaboration within the pharmaceutical sector
details
details
- Developing new antibiotics requires substantial investment, estimated at around 1 billion dollars, and typically takes 10 to 15 years, with a high failure rate of 95% for drug candidates
- The current antibiotic market is unsustainable due to low pricing and limited usage aimed at preventing resistance, highlighting the need for new economic models and government incentives
- Investment incentives for antibiotic development include push incentives like grants and clinical trial support, as well as pull incentives such as subscription models that separate revenue from drug usage
- The World Health Organization reports that there are approximately 15 drugs in development targeting superbugs, emphasizing the urgent need for improved conditions to attract pharmaceutical companies
details
details
details
details
The assumption that the development of new antibiotics will sufficiently address AMR overlooks the complex interplay of factors contributing to antibiotic resistance, such as over-prescription and agricultural use. Inference: Without addressing these root causes, the introduction of new drugs may only provide a temporary solution, failing to mitigate the rising mortality rates associated with superbugs.
This analysis is an original interpretation prepared by Art Argentum based on the transcript of the source video. The original video content remains the property of the respective YouTube channel. Art Argentum is not responsible for the accuracy or intent of the original material.